Shines its Spotlight on Generex Biotechnology Corporation (OTCBB: GNBT) Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express -- December 20, 2011 M2 PRESSWIRE-December20, 2011-Shines its Spotlight on Generex Biotechnology Corporation (OTCBB: GNBT) Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express -- December 20, 2011 M2 PRESSWIRE-December 20, 2011-Stockguru.com: Shines its Spotlight on Generex Biotechnology Corporation (OTCBB: GNBT) Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express -- December 20, 2011 (C)1994-2011 M2 COMMUNICATIONS RDATE:20122011 Dallas, Texas - StockGuru Shines its Spotlight on Generex Biotechnology Corporation (OTCBB: GNBT). The Company announced Friday that Bloomberg Television is scheduled to air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. The segment is scheduled to air at 6 pm EST (3 pm PST), Monday, December 19, 2011 . It is expected that, once aired, the segment will be available for viewing on the Bloomberg website and on the Generex website. The Company closed on December 19, 2011, at $0.175, trading in a fifty-two week range of $0.335 - 0.076. The story will cover the Company's novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37), which is the subject of an ongoing Phase 2 clinical study in patients with HER-2 expressing breast cancer. The segment will be featured in Bloomberg's "Innovators" segment, which focuses on world-changing technologies and innovations. The segment will include an interview by Bloomberg reporter Cali Carlin of Dr. Eric von Hofe, Ph.D., President of Antigen Express, and COL George E. Peoples, MD, FACS, Director, Cancer Vaccine Development Program. Antigen Express has pioneered technology for increasing the potency of therapeutic anti-cancer vaccines. Initial clinical studies showed that its lead compound, AE37, indeed showed surprisingly potent immunological activity without sacrificing any specificity in the immune response. For the last four years, AE37 has been in a controlled, randomized Phase II study to determine whether it can indeed prevent recurrences in patients who have had breast cancer. Positive interim results from that study were recently presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). Final Phase 2 results are expected in 2012. The Antigen Express AE37 breast cancer vaccine was also featured in Newsweek magazine on December 12, 2011 in science columnist and science editor Sharon Begley's article, Could This Be The End of Cancer?: About Generex Biotechnology Corporation Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.